Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2023; 13(15):5247-5265. doi:10.7150/thno.88998 This issue Cite

Review

The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning

Sajid Mushtaq1,2,✉, Park Ji Ae1, Jung Young Kim1, Kyo Chul Lee1, Kwang Il Kim1

1. Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS) Seoul 01812, Republic of Korea.
2. Department of Nuclear Engineering, Pakistan Institute of Engineering and Applied Sciences, P. O. Nilore, Islamabad 45650, Pakistan.

✉ Corresponding author: Sajid Mushtaq, Division of RI-Applied Research, Korea Institute of Radiological & Medical Sciences (KIRAMS) Seoul 01812, Republic of Korea. Telephone number: +02-970-1660; Fax number: +02-970-1341; E-mail address: sajidmush More

Citation:
Mushtaq S, Ae PJ, Kim JY, Lee KC, Kim KI. The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning. Theranostics 2023; 13(15):5247-5265. doi:10.7150/thno.88998. https://www.thno.org/v13p5247.htm
Other styles

File import instruction

Abstract

Graphic abstract

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are potent technologies for non-invasive imaging of pharmacological and biochemical processes in both preclinical and advanced clinical research settings. In the field of radiation therapy, boron neutron capture therapy (BNCT) stands out because it harnesses biological mechanisms to precisely target tumor cells while preserving the neighboring healthy tissues. To achieve the most favorable therapeutic outcomes, the delivery of boron-enriched tracers to tumors must be selective and efficient, with a substantial concentration of boron atoms meticulously arranged in and around the tumor cells. Although several BNCT tracers have been developed to facilitate the targeted and efficient delivery of boron to tumors, only a few have been labeled with PET or SPECT radionuclides. Such radiolabeling enables comprehensive in vivo examination, encompassing crucial aspects such as pharmacodynamics, pharmacokinetics, tumor selectivity, and accumulation and retention of the tracer within the tumor. This review provides a comprehensive summary of the essential aspects of BNCT tracers, focusing on their radiolabeling with PET or SPECT radioisotopes. This leads to more effective and targeted treatment approaches which ultimately enhance the quality of patient care with respect to cancer treatment.

Keywords: BNCT, PET, SPECT, radiolabeling, theranostics, targeted therapy

Citation styles

APA
Mushtaq, S., Ae, P.J., Kim, J.Y., Lee, K.C., Kim, K.I. (2023). The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning. Theranostics, 13(15), 5247-5265. https://doi.org/10.7150/thno.88998.

ACS
Mushtaq, S.; Ae, P.J.; Kim, J.Y.; Lee, K.C.; Kim, K.I. The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning. Theranostics 2023, 13 (15), 5247-5265. DOI: 10.7150/thno.88998.

NLM
Mushtaq S, Ae PJ, Kim JY, Lee KC, Kim KI. The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning. Theranostics 2023; 13(15):5247-5265. doi:10.7150/thno.88998. https://www.thno.org/v13p5247.htm

CSE
Mushtaq S, Ae PJ, Kim JY, Lee KC, Kim KI. 2023. The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning. Theranostics. 13(15):5247-5265.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use